NCT06034561View on ClinicalTrials.gov

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2029

Conditions
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed Remission
Interventions
DRUG

Bortezomib

Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.

Trial Locations (1)

01246000

RECRUITING

Instituto do Cancer do Estado de Sao Paulo, São Paulo

All Listed Sponsors
collaborator

Libbs Farmacêutica LTDA

INDUSTRY

lead

Instituto do Cancer do Estado de São Paulo

OTHER